Synthroid and Cannabis: The Full Interaction Profile for Levothyroxine Users

Does Cannabis Actually Interact with Synthroid?

Yes, cannabis interacts with Synthroid through pharmacokinetic pathways that are well-characterized for other drugs that share those same enzymatic routes. Levothyroxine is metabolized primarily by hepatic deiodination and conjugation, with CYP enzymes playing a secondary but clinically significant role in its disposition. THC and CBD modulate several of those same CYP isoforms, making the interaction plausible and, in some patients, measurable on TSH testing.

The FDA-approved Synthroid prescribing information does not list cannabis as a named interactant, but the label does warn broadly that "drugs that affect hepatic enzyme activity may alter levothyroxine metabolism." [1] That language encompasses any substance that induces or inhibits CYP1A2, CYP3A4, or CYP2C9, all of which are affected by cannabinoids or combustion products from cannabis smoke. [2]

What the Synthroid Label Does (and Does Not) Say

The current Synthroid prescribing information lists rifampin, carbamazepine, and phenytoin as CYP inducers that reduce levothyroxine exposure. [1] Cannabis smoke induces CYP1A2 via the polycyclic aromatic hydrocarbons generated by combustion, the same mechanism by which tobacco smoke reduces serum drug concentrations of clozapine and olanzapine. [3] The label does not name cannabis, but the pharmacological logic is identical.

CBD is handled differently. A 2020 review in Epilepsia summarized that Epidiolex (pharmaceutical cannabidiol 100 mg/mL) inhibits CYP3A4 and CYP2C9 at clinically relevant concentrations, raising plasma levels of co-administered substrates of those enzymes. [4] Levothyroxine is a partial CYP3A4 substrate, so CBD inhibition could slow its clearance and raise free T4, the opposite direction from smoked THC.

Magnitude: How Much Can TSH Shift?

No randomized controlled trial has specifically measured TSH change in levothyroxine-treated patients who begin or stop cannabis. That gap in the literature is real. What is known is that CYP1A2 induction by tobacco smoke can reduce plasma concentrations of CYP1A2-sensitive drugs by 30 to 50% in heavy smokers. [3] If smoked cannabis produces a comparable induction magnitude, a patient stable on 100 mcg/day of levothyroxine could drift into subclinical hypothyroidism without any change in dose.

How THC Affects Levothyroxine Metabolism

THC reaches peak plasma concentration within 3 to 10 minutes of inhalation and is extensively metabolized by CYP2C9 and CYP3A4 in the liver. [5] The combustion byproducts in smoked cannabis, particularly benzo[a]pyrene and other polycyclic aromatic hydrocarbons, induce CYP1A2 through activation of the aryl hydrocarbon receptor (AhR). [6]

CYP1A2 Induction by Smoke

CYP1A2 induction accelerates the oxidative metabolism of levothyroxine. The net effect is faster clearance, lower steady-state free T4, and compensatory TSH rise. A study published in Drug Metabolism and Pharmacokinetics confirmed that AhR-activating compounds in tobacco smoke are the dominant driver of CYP1A2 induction in smokers, not nicotine itself. [6] Cannabis smoke contains the same class of compounds. Vaporized or edible cannabis bypasses combustion and therefore does not induce CYP1A2 via this route.

THC as a Direct CYP2C9 Inhibitor

Beyond combustion byproducts, THC itself inhibits CYP2C9 in vitro. [5] This inhibition would predict higher, not lower, levothyroxine exposure if THC were the dominant variable. In practice, smoked cannabis delivers both CYP1A2-inducing combustion products and CYP2C9-inhibiting THC simultaneously, making the net direction of the interaction dependent on route of administration and frequency of use. Heavy daily smokers may show net induction; occasional edible users may show net inhibition of clearance.

THC and the Hypothalamic-Pituitary-Thyroid Axis

Animal data suggest that cannabinoid receptor 1 (CB1R) agonism can suppress TSH secretion directly at the hypothalamic level. A rodent study in Endocrinology showed that CB1R activation reduced TRH-stimulated TSH release in a dose-dependent manner. [7] Whether this translates to clinically significant pituitary suppression in humans using recreational cannabis doses remains uncertain, but it means TSH alone may underestimate the degree of thyroid dysfunction in a cannabis user on levothyroxine.

How CBD Affects Levothyroxine

CBD does not directly bind CB1R at typical doses. Its interaction with levothyroxine is almost entirely pharmacokinetic, mediated by CYP enzyme inhibition.

CYP3A4 and CYP2C9 Inhibition

The 2020 Epilepsia review of Epidiolex pharmacokinetics found that CBD at 20 mg/kg/day (the upper approved dose for Dravet syndrome) inhibits CYP3A4 and CYP2C9 with IC50 values well within clinically achievable plasma concentrations. [4] For patients on high-dose Epidiolex, this is a named concern in the FDA label for Epidiolex itself, which warns of interactions with CYP2C9 substrates including warfarin and phenytoin. [8]

OTC CBD products typically deliver 10 to 50 mg per dose, far below Epidiolex doses, so the CYP inhibition magnitude is likely smaller. Still, a patient using 150 to 300 mg/day of a high-potency CBD oil could reach plasma CBD concentrations sufficient to meaningfully inhibit CYP3A4 and slow levothyroxine clearance.

P-glycoprotein and Intestinal Absorption

CBD also inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) at the intestinal level. [9] P-gp is an efflux transporter that limits oral drug absorption. Inhibiting it can increase the fraction of levothyroxine absorbed from the gut. The Synthroid label already flags calcium carbonate, ferrous sulfate, and proton pump inhibitors as absorption-level interactants. [1] CBD-mediated P-gp inhibition represents an additional, less-recognized absorption modifier.

Does CBD Affect the Thyroid Gland Directly?

In vitro data from a 2020 paper in Molecules found that CBD reduced the viability of human thyroid carcinoma cells and altered iodine uptake in a concentration-dependent manner. [10] Whether this in vitro signal translates to effects on normal thyroid tissue at recreational CBD doses is unknown. Patients with Hashimoto thyroiditis who use CBD for inflammation or anxiety should still maintain their standard TSH monitoring schedule and report any new use to their prescribing clinician.

Absorption Timing: The Often-Overlooked Risk

Levothyroxine absorption depends on the 30 to 60 minute fasting window before eating after the morning dose. [1] Cannabis disrupts this window in two directions.

Appetite Stimulation and the Fasting Window

THC activates CB1R in the hypothalamus and stimulates ghrelin release, producing the well-described increase in appetite commonly called "the munchies." [11] A patient who medicates with cannabis in the morning and then eats within 20 minutes of taking Synthroid will have consistently lower levothyroxine absorption. Coffee, dairy, and high-fiber foods taken within that window can reduce absorption by 20 to 40%. [12] Adding food due to cannabis-stimulated appetite compounds that risk.

CBD and Reduced Appetite

High-dose CBD has the opposite appetite effect in some patients, reducing hunger through 5-HT1A receptor partial agonism. [13] A patient who skips breakfast due to CBD-related nausea or appetite suppression extends the fasting window, potentially increasing absorption. This patient might present with symptoms of overtreatment (palpitations, anxiety, tremor) without any dose change.

The HealthRX clinical team uses the following three-question framework when a levothyroxine patient reports cannabis use:

1. Route: Is the cannabis smoked (CYP1A2 induction risk) or ingested/vaped (no combustion-driven induction)?
2. Compound: Is it predominantly THC (net metabolic direction uncertain), CBD (CYP3A4 and P-gp inhibition), or both?
3. Timing: Does the patient consume cannabis within 2 hours of taking levothyroxine, and does it alter when they eat?

Each answer determines which direction TSH is likely to shift and how urgently a TSH recheck is needed.

Can You Drink Alcohol on Synthroid?

Alcohol is a separate but related question for patients on levothyroxine. Ethanol induces CYP2E1 and, at high chronic intake, induces CYP3A4, which could modestly accelerate levothyroxine clearance. [14] A study in Alcoholism: Clinical and Experimental Research found that chronic heavy alcohol use (more than 40 g ethanol/day) was independently associated with reduced serum T3 and T4 even in the absence of liver disease. [15] That suppression appears to be hypothalamic in origin, not hepatic.

Occasional, moderate alcohol use (1 to 2 standard drinks) is unlikely to produce a clinically meaningful shift in TSH in a stable levothyroxine patient. The greater concern is that heavy alcohol use and heavy cannabis use co-occur frequently, and their combined enzyme-modifying effects could be additive.

Alcohol and Morning Dosing

Alcohol consumed the night before does not meaningfully affect the next-morning levothyroxine absorption window, provided the patient is not vomiting (which would prevent adequate absorption) and takes the dose fasting as directed. Patients should take Synthroid on an empty stomach with water, not with any beverage containing calories or calcium. [1]

Monitoring Recommendations for Cannabis Users on Levothyroxine

The American Thyroid Association 2014 guidelines on hypothyroidism management state: "Serum TSH should be measured 4 to 8 weeks after any change in levothyroxine dose or brand, or after any change in factors affecting absorption or metabolism." [16] Cannabis use constitutes such a factor.

When to Recheck TSH

• Starting regular cannabis use after being stable on levothyroxine: recheck TSH at 6 to 8 weeks.
• Stopping regular cannabis use: recheck TSH at 6 to 8 weeks, as the inducing or inhibiting effect will wash out.
• Switching from smoked to edible or vaped forms: recheck TSH at 6 to 8 weeks, as the CYP1A2 induction signal will resolve.
• Starting pharmaceutical CBD (Epidiolex) concurrently with levothyroxine: consult prescribing clinician before starting; TSH recheck within 4 weeks. [8]

Signs That the Interaction May Be Affecting TSH Control

Symptoms of inadequate levothyroxine effect (rising TSH) include fatigue, constipation, weight gain, cold intolerance, and brain fog. Symptoms of excess levothyroxine effect (suppressed TSH) include heart palpitations, heat intolerance, anxiety, diarrhea, and unintended weight loss. Either cluster emerging after a change in cannabis use pattern warrants a TSH draw without waiting for the next scheduled lab.

Dose Adjustment Considerations

If TSH rises after a patient begins smoking cannabis daily, the likely cause is CYP1A2 induction accelerating levothyroxine clearance. The prescriber may increase the levothyroxine dose by 12.5 to 25 mcg and recheck TSH in 6 to 8 weeks. If the patient then stops smoking cannabis, the induction resolves and the higher dose may cause overtreatment; the dose will need to be stepped back down. Patients should not adjust their own levothyroxine dose based on symptoms alone.

Special Populations

Patients with Hashimoto Thyroiditis

Hashimoto thyroiditis involves chronic autoimmune inflammation of the thyroid. CBD has generated interest as an anti-inflammatory compound, and some Hashimoto patients use it for this purpose. A 2021 review in Frontiers in Immunology noted that CBD modulates T-regulatory cell function and may reduce pro-inflammatory cytokines in autoimmune conditions. [17] No controlled trial has examined CBD specifically in Hashimoto patients on levothyroxine. Clinicians should treat this use as they would any other CBD exposure: monitor TSH, not the reported symptom burden.

Patients with Thyroid Cancer on Suppressive Levothyroxine Therapy

Patients treated for differentiated thyroid cancer often receive levothyroxine at doses designed to keep TSH below 0.1 mIU/L. Any interaction that shifts TSH upward could undermine suppression therapy. These patients should disclose cannabis use to their oncologist or endocrinologist and may need more frequent TSH monitoring (every 4 to 6 weeks) during any change in use pattern.

Pregnant Patients

Levothyroxine requirements increase by approximately 30% during pregnancy, and TSH targets are tighter (<2.5 mIU/L in the first trimester per ACOG guidelines). [18] Cannabis use during pregnancy is not recommended by ACOG due to fetal risk. [19] For a pregnant patient who continues cannabis use, the pharmacokinetic interactions described above are superimposed on already-changing levothyroxine requirements, making frequent TSH monitoring (every 4 weeks in the first trimester) especially important.

Practical Guidance for Patients

Keep the levothyroxine dosing window consistent regardless of cannabis use patterns. Take Synthroid first thing in the morning, with 8 oz of water, 30 to 60 minutes before eating or drinking anything other than water. [1] If morning cannabis use consistently leads to eating too soon, shift either the cannabis use or the medication timing in consultation with the prescribing clinician.

Tell every prescriber and pharmacist about cannabis use. The interaction is not labeled, which means it will not appear in standard pharmacy drug-interaction checkers. Clinical disclosure is the only reliable way to ensure appropriate monitoring.

Do not self-adjust levothyroxine dose based on how you feel after starting or stopping cannabis. TSH can lag clinical symptoms by 4 to 6 weeks, and dose adjustments based on symptoms rather than labs frequently overshoot.